Tuning CRISPR/Cas9 activity with chemically modified nucleotide substitutions
AssigneesBoard of Trustees of Southern Illinois University, The Royal Institution for the Advancement of Learning/Mcgill University
InventorsKeith Gagnon, Masad Damha, Elise Malek-Adamian, Maryam Habibian, Daniel Timothy O'Reilly, Zachery Kartje
Life of this patent
Estimating the term…
Abstract
The present disclosure provides CRISPR/Cas9 ribonucleoprotein compositions comprising chemically modified CRISPR RNA (crRNA) guide and trans-acting CRISPR RNA (tracrRNA) components. Methods of using the disclosed CRISPR/Cas9 ribonucleoprotein compositions are also provided.
Claims14
A composition comprising a Cas9 protein, a first oligonucleotide comprising a first region having a 5′ end and a 3′ end and a second region, and a second oligonucleotide comprising a first region and a second region, wherein said second region of said first oligonucleotide interacts with said first region of said second oligonucleotide, and said second region of said second oligonucleotide interacts with said Cas9 protein, wherein all nucleotides of said first oligonucleotide are 2′-deoxyribonucleotides or 2′-deoxyribonucleotide analogs.
Dependencies are inferred from the claim text.